A Phase 1 dose extension study of TRX100 (tivoxavir marboxil)
Latest Information Update: 21 Aug 2024
At a glance
- Drugs Tivoxavir marboxil (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- 15 Aug 2024 According to a Traws Pharma media release, company has started dosing in first cohort, and will announce topline results from Australia in Q4 2024. And Initiation of Phase 2 efficacy study is expected in Q4 2024 or Q1 2025.
- 15 Aug 2024 Status changed from planning to recruiting, according to Traws Pharma media release.
- 30 May 2024 New trial record